UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 494

Sortiert nach

Improving treatment of HER2-positive cancers: opportunities and challenges

Science translational medicine, 2012-03, Vol.4 (127), p.127rv2

Stern, Howard M

2012

Volltextzugriff (PDF)

Diverse somatic mutation patterns and pathway alterations in human cancers

Nature (London), 2010-08, Vol.466 (7308), p.869-873

2010

Volltextzugriff (PDF)

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

Cancer research (Chicago, Ill.), 2008-07, Vol.68 (14), p.5878-5887

2008

Volltextzugriff (PDF)

Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents

The Journal of cell biology, 2008-10, Vol.183 (1), p.101-116

2008

Volltextzugriff (PDF)

TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer

Science signaling, 2011-06, Vol.4 (177), p.ra41

2011

Volltextzugriff (PDF)

Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers

Proceedings of the National Academy of Sciences - PNAS, 2012-11, Vol.109 (47), p.19368-19373

2012

Volltextzugriff (PDF)

Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer

Nature communications, 2014-05, Vol.5 (1), p.3830-3830, Article 3830

2014

Volltextzugriff (PDF)

Cancer genetics and drug discovery in the zebrafish

Nature reviews. Cancer, 2003-07, Vol.3 (7), p.533-539

2003

Volltextzugriff (PDF)

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)

Breast cancer research and treatment, 2013-02, Vol.138 (1), p.99-108

2013

Volltextzugriff (PDF)

Oncogenic BRAF is required for tumor growth and maintenance in melanoma models

Cancer research (Chicago, Ill.), 2006-01, Vol.66 (2), p.999-1006

2006

Volltextzugriff (PDF)

Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab

Clinical cancer research, 2010-03, Vol.16 (5), p.1587-1596

2010

Volltextzugriff (PDF)

A Chemical Genetic Screen for Cell Cycle Inhibitors in Zebrafish Embryos

Chemical biology & drug design, 2006-10, Vol.68 (4), p.213-219

2006

Volltextzugriff (PDF)

Effects of lethal irradiation in zebrafish and rescue by hematopoietic cell transplantation

Blood, 2004-09, Vol.104 (5), p.1298-1305

2004

Volltextzugriff (PDF)

A Zebrafish bmyb Mutation Causes Genome Instability and Increased Cancer Susceptibility

Proceedings of the National Academy of Sciences - PNAS, 2005-09, Vol.102 (37), p.13194-13199

2005

Volltextzugriff (PDF)

Oncogenic Activating Mutations Are Associated with Local Copy Gain

Molecular cancer research, 2009-08, Vol.7 (8), p.1244-1252

2009

Volltextzugriff (PDF)

A mutation in separase causes genome instability and increased susceptibility to epithelial cancer

Genes & development, 2007-01, Vol.21 (1), p.55-59

2007

Volltextzugriff (PDF)

PPM1H is a p27 phosphatase implicated in trastuzumab resistance

Cancer discovery, 2011-09, Vol.1 (4), p.326-337

2011

Volltextzugriff (PDF)

The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients

Genome research, 2012-04, Vol.22 (4), p.593

2012

Volltextzugriff (PDF)

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

American journal of hematology, 2018-11, Vol.93 (11), p.1318-1326

2018

Volltextzugriff (PDF)

Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

Clinical cancer research, 2012-06, Vol.18 (12), p.3478-3486

2012

Volltextzugriff (PDF)

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Clinical cancer research, 2015-05, Vol.21 (9), p.2065-2074

2015

Volltextzugriff (PDF)

Zebrafish as a cancer model system

Cancer cell, 2002-04, Vol.1 (3), p.229-231

2002

Volltextzugriff (PDF)

1 – 25 von 494

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(474)
Mit Volltextzugriff
(400)

Publikationsform

Sprache

Englisch
(493)
Japanisch
(118)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(401)
Humans
(344)
Life Sciences & Biomedicine
(301)
Female
(238)
Male
(233)
Aged
(199)
Alzheimer's Disease
(146)
Neurosciences & Neurology
(146)
Middle Aged
(129)
Aged, 80 And Over
(113)
Neuroimaging
(105)
Neurosciences
(102)
Biological And Medical Sciences
(97)
Medical Imaging
(85)
Magnetic Resonance Imaging
(84)
Medical Sciences
(78)
Neurology
(77)
Science & Technology - Other Topics
(75)
Multidisciplinary Sciences
(73)
Biomarkers
(71)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Improving treatment of HER2-positive cancers: opportunities and challenges

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

Diverse somatic mutation patterns and pathway alterations in human cancers

Oncogenic ERBB3 Mutations in Human Cancers

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events

Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents

TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer

Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers

Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer

Cancer genetics and drug discovery in the zebrafish

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)

Oncogenic BRAF is required for tumor growth and maintenance in melanoma models

Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab

A Chemical Genetic Screen for Cell Cycle Inhibitors in Zebrafish Embryos

Effects of lethal irradiation in zebrafish and rescue by hematopoietic cell transplantation

A Zebrafish bmyb Mutation Causes Genome Instability and Increased Cancer Susceptibility

Oncogenic Activating Mutations Are Associated with Local Copy Gain

A mutation in separase causes genome instability and increased susceptibility to epithelial cancer

PPM1H is a p27 phosphatase implicated in trastuzumab resistance

The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Zebrafish as a cancer model system

Suchergebnisse filtern